Literature DB >> 1416862

Analysis of vancomycin time-kill studies with Staphylococcus species by using a curve stripping program to describe the relationship between concentration and pharmacodynamic response.

B H Ackerman1, A M Vannier, E B Eudy.   

Abstract

Mono- and biexponential killing curves for vancomycin over a 2- to 50-micrograms/ml concentration range were generated for 11 Staphylococcus aureus isolates and 12 coagulase-negative Staphylococcus species in the logarithmic phase of growth. Nonlinear least-squares regression of the initial growth rate and disappearance were not significantly different for lower or higher concentrations of vancomycin in broth.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1416862      PMCID： PMC192044          DOI： 10.1128/AAC.36.8.1766

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  25 in total

1.  Activity of intracellular antibiotics.

Authors:  P Van der Auwera; G Prinz; G Petrikkos
Journal:  Infection       Date:  1991       Impact factor: 3.553

2.  Evaluation of three methods for determining initial vancomycin doses.

Authors:  B H Ackerman
Journal:  DICP       Date:  1989-02

3.  Application of a Bayesian method to monitor and adjust vancomycin dosage regimens.

Authors:  A K Hurst; M A Yoshinaga; G H Mitani; K A Foo; R W Jelliffe; E C Harrison
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

4.  In-vitro activity of vancomycin, teicoplanin, daptomycin, ramoplanin, MDL 62873 and other agents against staphylococci, enterococci and Clostridium difficile.

Authors:  A Bartoloni; M G Colao; A Orsi; R Dei; E Giganti; F Parenti
Journal:  J Antimicrob Chemother       Date:  1990-11       Impact factor: 5.790

5.  Laboratory evaluation of five assay methods for vancomycin: bioassay, high-pressure liquid chromatography, fluorescence polarization immunoassay, radioimmunoassay, and fluorescence immunoassay.

Authors:  M A Pfaller; D J Krogstad; G G Granich; P R Murray
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

6.  ESTRIP, a BASIC computer program for obtaining initial polyexponential parameter estimates.

Authors:  R D Brown; J E Manno
Journal:  J Pharm Sci       Date:  1978-12       Impact factor: 3.534

7.  In vitro antimicrobial activity of imipenem in combination with vancomycin or teicoplanin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  J G Barr; E T Smyth; G M Hogg
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

8.  Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. The Infectious Diseases Consortium of Oregon.

Authors:  D N Gilbert; C A Wood; R C Kimbrough
Journal:  Antimicrob Agents Chemother       Date:  1991-01       Impact factor: 5.191

9.  Development of in-vitro resistance to glycopeptide antibiotics: assessment in staphylococci of different species.

Authors:  F Biavasco; E Giovanetti; M P Montanari; R Lupidi; P E Varaldo
Journal:  J Antimicrob Chemother       Date:  1991-01       Impact factor: 5.790

10.  Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts.

Authors:  P Van der Auwera; M Aoun; F Meunier
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191
View more
  23 in total

1.  Levels of vancomycin in the cerebral interstitial fluid after severe head injury.

Authors:  Anselmo Caricato; Mariano Pennisi; Aldo Mancino; Gianluca Vigna; Claudio Sandroni; Andrea Arcangeli; Massimo Antonelli
Journal:  Intensive Care Med       Date:  2006-01-24       Impact factor: 17.440

2.  A pharmacodynamic model for the action of the antibiotic imipenem on Pseudomonas aeruginosa populations in vitro.

Authors:  P H Berg; E O Voit; R L White
Journal:  Bull Math Biol       Date:  1996-09       Impact factor: 1.758

3.  Constant rate infusion of vancomycin in premature neonates: a new dosage schedule.

Authors:  F Pawlotsky; A Thomas; M F Kergueris; T Debillon; J C Roze
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

Review 4.  Alternative strategies for proof-of-principle studies of antibacterial agents.

Authors:  Axel Dalhoff; Andrej Weintraub; Carl Erik Nord
Journal:  Antimicrob Agents Chemother       Date:  2014-05-27       Impact factor: 5.191

5.  Pharmacodynamics of vancomycin alone and in combination with gentamicin at various dosing intervals against methicillin-resistant Staphylococcus aureus-infected fibrin-platelet clots in an in vitro infection model.

Authors:  H H Houlihan; R C Mercier; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

6.  Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery.

Authors:  Keso Skhirtladze; Doris Hutschala; Tatjana Fleck; Florian Thalhammer; Marek Ehrlich; Thomas Vukovich; Markus Müller; Edda M Tschernko
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

7.  Efficacious Analogs of the Lantibiotic Mutacin 1140 against a Systemic Methicillin-Resistant Staphylococcus aureus Infection.

Authors:  Mengxin Geng; Akshaya Ravichandran; Jerome Escano; Leif Smith
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

Review 8.  Pharmacokinetic optimisation of vancomycin therapy.

Authors:  W G Leader; M H Chandler; M Castiglia
Journal:  Clin Pharmacokinet       Date:  1995-04       Impact factor: 6.447

9.  The management of infection and colonization due to methicillin-resistant Staphylococcus aureus: A CIDS/CAMM position paper.

Authors:  Andrew E Simor; Mark Loeb
Journal:  Can J Infect Dis       Date:  2004-01

10.  Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections.

Authors:  J K James; S M Palmer; D P Levine; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.